Duloxetine for neuropathic pain based on recent clinical trials

David A Fishbain, Kim Berman, Daniel K. Kajdasz

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The treatment of neuropathic pain with antidepressants has a long history. Early studies were contradictory and were limited by small numbers of patients. When evaluated meta-analytically, these studies indicated that antidepressants do have efficacy for neuropathic pain. However, none of the antidepressants used in these studies have gained approval by the US Food and Drug Administration (FDA) for this indication, and were generally associated with a high side-effect burden. Recently, duloxetine, a dual-action reuptake inhibitor, has demonstrated significant efficacy in the management of diabetic peripheral neuropathic pain in three double-blind, placebo-controlled trials and was approved by the FDA for this indication. These studies are discussed in this article.

Original languageEnglish
Pages (from-to)199-204
Number of pages6
JournalCurrent Pain and Headache Reports
Volume10
Issue number3
DOIs
StatePublished - Jun 1 2006

Fingerprint

Neuralgia
Antidepressive Agents
Clinical Trials
United States Food and Drug Administration
History
Placebos
Duloxetine Hydrochloride
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Duloxetine for neuropathic pain based on recent clinical trials. / Fishbain, David A; Berman, Kim; Kajdasz, Daniel K.

In: Current Pain and Headache Reports, Vol. 10, No. 3, 01.06.2006, p. 199-204.

Research output: Contribution to journalArticle

Fishbain, David A ; Berman, Kim ; Kajdasz, Daniel K. / Duloxetine for neuropathic pain based on recent clinical trials. In: Current Pain and Headache Reports. 2006 ; Vol. 10, No. 3. pp. 199-204.
@article{67a3b46d6e7641d7a4d809483d0dd7d2,
title = "Duloxetine for neuropathic pain based on recent clinical trials",
abstract = "The treatment of neuropathic pain with antidepressants has a long history. Early studies were contradictory and were limited by small numbers of patients. When evaluated meta-analytically, these studies indicated that antidepressants do have efficacy for neuropathic pain. However, none of the antidepressants used in these studies have gained approval by the US Food and Drug Administration (FDA) for this indication, and were generally associated with a high side-effect burden. Recently, duloxetine, a dual-action reuptake inhibitor, has demonstrated significant efficacy in the management of diabetic peripheral neuropathic pain in three double-blind, placebo-controlled trials and was approved by the FDA for this indication. These studies are discussed in this article.",
author = "Fishbain, {David A} and Kim Berman and Kajdasz, {Daniel K.}",
year = "2006",
month = "6",
day = "1",
doi = "10.1007/s11916-006-0046-7",
language = "English",
volume = "10",
pages = "199--204",
journal = "Current Pain and Headache Reports",
issn = "1531-3433",
publisher = "Current Science, Inc.",
number = "3",

}

TY - JOUR

T1 - Duloxetine for neuropathic pain based on recent clinical trials

AU - Fishbain, David A

AU - Berman, Kim

AU - Kajdasz, Daniel K.

PY - 2006/6/1

Y1 - 2006/6/1

N2 - The treatment of neuropathic pain with antidepressants has a long history. Early studies were contradictory and were limited by small numbers of patients. When evaluated meta-analytically, these studies indicated that antidepressants do have efficacy for neuropathic pain. However, none of the antidepressants used in these studies have gained approval by the US Food and Drug Administration (FDA) for this indication, and were generally associated with a high side-effect burden. Recently, duloxetine, a dual-action reuptake inhibitor, has demonstrated significant efficacy in the management of diabetic peripheral neuropathic pain in three double-blind, placebo-controlled trials and was approved by the FDA for this indication. These studies are discussed in this article.

AB - The treatment of neuropathic pain with antidepressants has a long history. Early studies were contradictory and were limited by small numbers of patients. When evaluated meta-analytically, these studies indicated that antidepressants do have efficacy for neuropathic pain. However, none of the antidepressants used in these studies have gained approval by the US Food and Drug Administration (FDA) for this indication, and were generally associated with a high side-effect burden. Recently, duloxetine, a dual-action reuptake inhibitor, has demonstrated significant efficacy in the management of diabetic peripheral neuropathic pain in three double-blind, placebo-controlled trials and was approved by the FDA for this indication. These studies are discussed in this article.

UR - http://www.scopus.com/inward/record.url?scp=33745324475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745324475&partnerID=8YFLogxK

U2 - 10.1007/s11916-006-0046-7

DO - 10.1007/s11916-006-0046-7

M3 - Article

VL - 10

SP - 199

EP - 204

JO - Current Pain and Headache Reports

JF - Current Pain and Headache Reports

SN - 1531-3433

IS - 3

ER -